HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ferenc Nagy Selected Research

CT-P13

11/2018Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.
11/2017Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
11/2017Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.
8/2017Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
11/2016Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
2/2016Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
1/2015Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ferenc Nagy Research Topics

Disease

30Ulcerative Colitis
11/2020 - 05/2003
25Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/2021 - 12/2002
22Crohn Disease (Crohn's Disease)
11/2020 - 12/2002
12Parkinson Disease (Parkinson's Disease)
01/2019 - 01/2008
9Hypersensitivity (Allergy)
02/2016 - 06/2004
5Neoplasms (Cancer)
01/2021 - 06/2002
4Encephalitis (Encephalitis, Rasmussen)
01/2018 - 08/2014
4Tremor (Tremors)
01/2014 - 03/2006
3Autoimmune Diseases of the Nervous System
01/2021 - 07/2016
3Limbic Encephalitis (Paraneoplastic Limbic Encephalitis)
01/2018 - 08/2014
3Glioma (Gliomas)
05/2017 - 08/2014
3Pouchitis
03/2015 - 12/2008
3Fistula
02/2015 - 09/2009
3Human Influenza (Influenza)
02/2015 - 02/2011
2Stroke (Strokes)
11/2021 - 06/2003
2Inflammation (Inflammations)
01/2021 - 07/2010
2Photophobia (Light Sensitivity)
01/2020 - 01/2011
2Nausea
03/2018 - 03/2012
2Gastrointestinal Diseases (Functional Gastrointestinal Disorders)
01/2018 - 02/2013
2Migraine Disorders (Migraine)
09/2017 - 07/2010
2Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
06/2015 - 05/2007
2Diarrhea
02/2013 - 05/2007
2Dystonia (Limb Dystonia)
07/2012 - 01/2008
2Infections
07/2012 - 01/2007
2Essential Tremor (Essential Tremors)
03/2012 - 01/2008
2Proctitis
07/2009 - 10/2004
2Pneumonia (Pneumonitis)
01/2007 - 02/2006
2Interstitial Lung Diseases (Interstitial Lung Disease)
01/2007 - 02/2006
2Cerebrovascular Disorders (Cerebrovascular Occlusion)
06/2003 - 05/2003
1Muscle Spasticity (Spastic)
06/2022
1COVID-19
05/2022
1Cerebral Infarction
11/2021
1Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
11/2021
1Partial Epilepsies (Epilepsy, Partial)
09/2021
1Metabolic Diseases (Metabolic Disease)
09/2021
1Anti-N-Methyl-D-Aspartate Receptor Encephalitis
01/2021
1Microscopic Colitis
01/2021
1Necrosis
01/2021
1Multiple Sclerosis
01/2020
1Ophthalmoplegia (External Ophthalmoplegia)
03/2018
1Dizziness (Lightheadedness)
03/2018
1Diplopia (Double Vision)
03/2018
1Paralysis (Palsy)
03/2018
1Testicular Neoplasms (Testicular Cancer)
01/2018
1Cognitive Dysfunction
07/2016
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
07/2016

Drug/Important Bio-Agent (IBA)

21Infliximab (Remicade)FDA Link
11/2018 - 01/2004
11Pharmaceutical PreparationsIBA
09/2021 - 05/2003
10SteroidsIBA
11/2020 - 05/2003
8Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2020 - 01/2004
7CT-P13IBA
11/2018 - 01/2015
7Biosimilar PharmaceuticalsIBA
11/2018 - 01/2015
7Proteins (Proteins, Gene)FDA Link
01/2018 - 06/2004
6AntibodiesIBA
07/2016 - 01/2006
5Adalimumab (Humira)FDA Link
05/2016 - 06/2011
5Cyclosporine (Ciclosporin)FDA LinkGeneric
04/2014 - 05/2003
4Azathioprine (Imuran)FDA LinkGeneric
11/2016 - 02/2006
4Leukocyte L1 Antigen Complex (Calgranulin)IBA
01/2016 - 02/2013
3AutoantibodiesIBA
01/2021 - 05/2013
3Immunologic Factors (Immunomodulators)IBA
11/2020 - 02/2011
3Monoclonal AntibodiesIBA
11/2018 - 09/2011
2VaccinesIBA
05/2022 - 02/2015
2Budesonide (Pulmicort)FDA LinkGeneric
01/2021 - 10/2004
2PhytochromeIBA
01/2020 - 10/2004
2Matrix Metalloproteinases (MMPs)IBA
03/2015 - 02/2013
2Influenza Vaccines (Influenza Vaccine)FDA Link
02/2015 - 11/2012
2Immunosuppressive Agents (Immunosuppressants)IBA
02/2015 - 11/2012
2SodiumIBA
08/2014 - 07/2010
2Pramipexole (Mirapex)FDA LinkGeneric
03/2012 - 02/2011
2Sodium-Hydrogen ExchangersIBA
04/2011 - 07/2010
1Complement System Proteins (Complement)IBA
11/2021
1Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
09/2021
1HomocysteineIBA
09/2021
1vedolizumabIBA
01/2020
1TabletsIBA
03/2018
1Telmisartan (Micardis)FDA Link
03/2018
1AntigensIBA
01/2018
1Cell Surface ReceptorsIBA
01/2018
1Acetic Acid (Vinegar)FDA LinkGeneric
09/2017
15-hydroxyindoleIBA
09/2017
1Anti-Bacterial Agents (Antibiotics)IBA
11/2016
1GABA Receptors (GABA Receptor)IBA
07/2016
1Pyruvate KinaseIBA
01/2016
1HaptoglobinsIBA
01/2016
1Matrix Metalloproteinase 9 (Gelatinase B)IBA
01/2016
1Hemoglobins (Hemoglobin)IBA
01/2016
1Leucine (L-Leucine)FDA Link
07/2015
1Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA
07/2015

Therapy/Procedure

40Therapeutics
11/2021 - 12/2002
10Biological Therapy
01/2018 - 02/2011
6Deep Brain Stimulation
11/2015 - 03/2006
4Colectomy
04/2014 - 06/2002
3Immunotherapy
01/2021 - 08/2014
3Activities of Daily Living (ADL)
01/2019 - 03/2012
2Exercise Therapy (Therapy, Exercise)
01/2020 - 12/2018
2Complementary Therapies (Alternative Medicine)
01/2018 - 09/2010
2Critical Care (Surgical Intensive Care)
01/2018 - 01/2007
1Catheters
06/2022
1Thrombectomy
11/2021
1Telescopes
03/2018